192 related articles for article (PubMed ID: 31029744)
1. Linc00221 modulates cisplatin resistance in non-small-cell lung cancer via sponging miR-519a.
Tang H; Han X; Li M; Li T; Hao Y
Biochimie; 2019 Jul; 162():134-143. PubMed ID: 31029744
[TBL] [Abstract][Full Text] [Related]
2. SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer.
Jiao P; Hou J; Yao M; Wu J; Ren G
Biomed Pharmacother; 2019 Sep; 117():109164. PubMed ID: 31252267
[TBL] [Abstract][Full Text] [Related]
3. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
Wang L; Shang X; Feng Q
Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
[TBL] [Abstract][Full Text] [Related]
4. Exosomal circ_PIP5K1A regulates the progression of non-small cell lung cancer and cisplatin sensitivity by miR-101/ABCC1 axis.
Shao N; Song L; Sun X
Mol Cell Biochem; 2021 Jun; 476(6):2253-2267. PubMed ID: 33570734
[TBL] [Abstract][Full Text] [Related]
5. MiR-519a functions as a tumor suppressor and is negatively associated with poor prognosis of non-small cell lung cancer.
Wang Y; Jiang F; Wang J; Fu Y; Li Y; Li F
Cancer Biomark; 2020; 28(1):121-128. PubMed ID: 32224524
[TBL] [Abstract][Full Text] [Related]
6. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
Huang Q; Xing S; Peng A; Yu Z
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA FENDRR inhibits NSCLC cell growth and aggressiveness by sponging miR-761.
Zhang MY; Zhang ZL; Cui HX; Wang RK; Fu L
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8324-8332. PubMed ID: 30556873
[TBL] [Abstract][Full Text] [Related]
8. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
9. LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4.
Hu B; Zhang H; Wang Z; Zhang F; Wei H; Li L
Cancer Biol Ther; 2017 Dec; 18(12):974-983. PubMed ID: 29020498
[TBL] [Abstract][Full Text] [Related]
10. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling.
Tang Y; Xiao G; Chen Y; Deng Y
Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897
[TBL] [Abstract][Full Text] [Related]
11. LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway.
Xu L; Xu Y; Yang M; Li J; Xu F; Chen BL
BMC Pulm Med; 2020 Oct; 20(1):266. PubMed ID: 33059643
[TBL] [Abstract][Full Text] [Related]
12. Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p.
Ma G; Zhu J; Liu F; Yang Y
DNA Cell Biol; 2019 Feb; 38(2):176-183. PubMed ID: 30601026
[TBL] [Abstract][Full Text] [Related]
13. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis.
Cao L; Chen J; Ou B; Liu C; Zou Y; Chen Q
Biomed Pharmacother; 2017 Sep; 93():570-579. PubMed ID: 28686971
[TBL] [Abstract][Full Text] [Related]
14. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer.
Shen Q; Xu Z; Xu S
Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379
[TBL] [Abstract][Full Text] [Related]
15. LINC02389/miR-7-5p Regulated Cisplatin Resistance of Non-Small-Cell Lung Cancer via Promoting Oxidative Stress.
Ma P; Han W; Meng C; Tan X; Liu P; Dong L
Anal Cell Pathol (Amst); 2022; 2022():6100176. PubMed ID: 36311891
[TBL] [Abstract][Full Text] [Related]
16. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S
Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948
[TBL] [Abstract][Full Text] [Related]
17. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
[TBL] [Abstract][Full Text] [Related]
18. The long intergenic noncoding RNA GAS5 reduces cisplatin-resistance in non-small cell lung cancer through the miR-217/LHPP axis.
Yang X; Meng L; Zhong Y; Hu F; Wang L; Wang M
Aging (Albany NY); 2021 Jan; 13(2):2864-2884. PubMed ID: 33418541
[TBL] [Abstract][Full Text] [Related]
19. The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis.
Chen L; Han X; Hu Z; Chen L
Cancer Chemother Pharmacol; 2019 May; 83(5):921-931. PubMed ID: 30859368
[TBL] [Abstract][Full Text] [Related]
20. Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
Huang J; Lin C; Dong H; Piao Z; Jin C; Han H; Jin D
Cancer Chemother Pharmacol; 2020 Nov; 86(5):663-672. PubMed ID: 33030583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]